ACE Inhibitors Market: Information
by Drug (Lisinopril, Ramipril, Enalapril, Benazepril, Fosinopril, Captopril,
Moexipril and others), Application
(Heart Failure, Hypertension, Diabetes, Heart Attack, Chronic Kidney Disease
and others), Dosage Form (Oral Tablets and Oral Solution), Distribution Channel
(Retail Pharmacy, Hospital Pharmacy, E-commerce Websites and Online Drug Stores)
and Region (Americas, Europe, Asia-Pacific and the Middle East & Africa) -
Forecast till 2025
Market Highlights
According to MRFR analysis, ACE
Inhibitors Market is expected to register a CAGR of 3.10% during
the forecast period of 2019 to 2025 and is likely to be valued at USD
7682.8 Million in 2025.
The growth of the global ACE
inhibitors market is determined by numerous factors such as rising adoption of
ACE inhibitors for the treatment of cardiovascular complications and diabetic
neuropathy, rising cases of cardiovascular disorders such as hypertension, and
surge in demand for less expensive drugs. For instance, according to the data
published by the World Health Organization (WHO) in 2017, the global prevalence
rate of raised blood pressure in adults aged more than 18 was estimated to be
22.1% in 2017. However, side effects associated with the treatment and high
costs of treatment are likely to hamper the growth of the global ACE inhibitors
market during the forecast period.
Regional Analysis
The market has been divided, by
region, into the Americas, Europe, Asia-Pacific, and the Middle East &
Africa.
Americas has been segmented into
North America and Latin America, with the North American market being divided
into the US and Canada. The Americas is projected to hold the largest market
share owing to the growing prevalence of hypertension and cardiovascular
disorders.
The European ACE inhibitors market
has been categorized as Western Europe and Eastern Europe. The Western European
market has further been classified as Germany, France, the UK, Italy, Spain,
and the rest of Western Europe. The ACE inhibitors market in Asia-Pacific has
been segmented into Japan, China, India, South Korea, Australia, and the rest
of Asia-Pacific. The presence of a huge population base, increasing awareness
about cardiovascular disorders, and rising disposable income are the key
factors responsible for the fastest growth of the market in Asia-Pacific. The
ACE inhibitors market in the Middle East & Africa has been divided into the
Middle East and Africa.
Segmentation
The Global ACE Inhibitors Market has
been segmented based on Product, Application, Dosage Form, and Distribution
Channel.
The market, based on product, has
been divided into lisinopril, ramipril, enalapril, benazepril, fosinopril,
captopril, moexipril, and others. The lisinopril is likely to hold the maximum
market share in the global ACE inhibitors market owing to the growing adoption
of lisinopril in the management of cardiovascular complications and diabetic
neuropathy.
The global ACE inhibitors
market based on the application has been segregated into heart failure,
hypertension, diabetes, heart attack, chronic kidney disease, and others. The
hypertension segment is expected to hold a larger share of the market share
owing to the rising cases of hypertension and the adoption of ACE inhibitors.
The dosage form segment of the market
is divided into oral tablets and oral solution. Capoten, Vasotec, Prinivil,
Zestril, Lotensin, Monopril, and Altace are some well-known and widely used
oral tablets.
Based on distribution
channel, the global ACE inhibitors market has
been segmented into retail pharmacy, hospital pharmacy, e-commerce websites and
online drug stores, and others. Retail pharmacy holds maximum market share
during the forecast period.
Key Players
Some of the Key Players
in the Global ACE Inhibitors Market are Bristol-Myers Squibb Company (US), Par
Pharmaceutical Companies, Inc. (US), UCB, Inc. (Belgium), Pfizer, Inc.(US),
AbbVie Inc.(US), AstraZeneca (UK), Bausch Health Companies Inc.(Canada),
Novartis AG (Switzerland), Merck & Co., Inc.(US), Teva Pharmaceutical
Industries Ltd.(Israel), Silvergate Pharmaceuticals, Inc. (US), and others.
No comments:
Post a Comment